# Alta Life Sciences

> Alta Life Sciences is a VC fund backing Biotechnology and Health Care. See 18 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Barcelona, Spain
- Total investments: 18
- Last investment: Jun 2026
- Lead investor: 50%
- Last updated: Aug 2026
- Website: https://www.altals.com/

Alta Life Sciences is a leading multistage venture capital investment firm. Alta LS will invest in companies at all stages of development: from seed financing through commercial growth. Alta LS invests in all areas of life sciences including biotechnology, medical devices, diagnostics, genomics and digital health.

## Contacts

5 contacts available for Alta Life Sciences. Shizune tracks 5 team members at Alta Life Sciences. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/alta-life-sciences?utm_source=investor_profile

## Round sizes

| Stage | Round size |
| --- | --- |
| Series A | $3M–$33M |
| Series B | $13M–$87M |
| Venture - Series Unknown | $3.3M–$13M |

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 8 | 44% |
| Health Care | 6 | 33% |
| Therapeutics | 3 | 17% |
| Medical Device | 3 | 17% |
| Medical | 2 | 11% |

17 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 7 | 39% |
| Venture - Series Unknown | 4 | 22% |
| Series B | 2 | 11% |
| Seed | 1 | 6% |
| Series D | 1 | 6% |

7 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| Spain | 8 | 44% |
| United States | 2 | 11% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Guy P. Nohra | Managing General Partner | 9 | https://shizune.co/investors/profile/guy-p-nohra |
| Scott Moonly | General Partner | 3 | https://shizune.co/investors/profile/scott-moonly |
| José Antonio Mesa | Partner | 7 | https://shizune.co/investors/profile/jos-antonio-mesa |
| Miguel Valls | General Partner | 0 | https://shizune.co/investors/profile/miguel-valls |
| Montserrat Vendrell | Partner | 1 | https://shizune.co/investors/profile/montserrat-vendrell |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Ona Therapeutics | Ona Therapeutics is a biotech company that specializes in the discovery and development of therapeutic biologics targeting tumor metastatic-initiating cells and lipid metabolism. Founded in 2019 by Salvador Aznar-Benitah and Valerie Vanhooren, it was a spin-off from ICREA and Advanced Studies, and the IRB Institute for Research in Biomedicine. | $86.6M | Series B | Jun 04, 2026 |  |
| Peptomyc | Peptomyc is a company focused on the development of a new generation of cell-penetrating peptides (CPPs) targeting the Myc oncoprotein for cancer treatment. The company was founded in December 2014 and it is based on Dr. Soucek’s scientific research in Omomyc (the best direct Myc inhibitor known to date) over the last twenty years.Currently,cancer incidence in the world exceeds 14 million cases per year and results in 8 million deaths annually. Moreover, such numbers are forecast to rise by 75% over the next 20 years (World Cancer Report. International Agency for Research on Cancer 2014). At the moment, standard therapies include surgery, radiotherapy, chemotherapy, and, in a restricted subset of cancers, precision medicine. Unfortunately, very often these therapies fail, due to the development of resistance.Peptomyc has adopted a different strategy based on the inhibition of the oncoprotein Myc, which is found deregulated in the majority of human cancers. Myc holds a non-redundant function in cancer around which tumors cannot evolve, hence targeting Myc is the most promising therapeutic opportunity to date. Although Myc plays a central role in cancer there is currently no Myc inhibitor in the market. | $5.8M | Venture - Series Unknown | Mar 24, 2026 |  |
| Ona Therapeutics | Ona Therapeutics is a biotech company that specializes in the discovery and development of therapeutic biologics targeting tumor metastatic-initiating cells and lipid metabolism. Founded in 2019 by Salvador Aznar-Benitah and Valerie Vanhooren, it was a spin-off from ICREA and Advanced Studies, and the IRB Institute for Research in Biomedicine. | $11.6M | Venture - Series Unknown | Oct 09, 2025 |  |
| DeepUll | DeepUll is a biotech company that focuses its activity on the development of a new diagnostic system for early-stage sepsis condition. DeepUll’s proposal is based on quickly identifying the pathogens and offering the antibiogram within a few hours on the one hand, and on using the data and learning about the patient’s immunological and functionalstatus on the other. The system allows doctors to predict the future appearance and evolution of sepsis within a short period of time and thus provide a suitable clinical response even before the symptoms arise. | $12.7M | Series B | Oct 20, 2022 |  |
| Peptomyc | Peptomyc is a company focused on the development of a new generation of cell-penetrating peptides (CPPs) targeting the Myc oncoprotein for cancer treatment. The company was founded in December 2014 and it is based on Dr. Soucek’s scientific research in Omomyc (the best direct Myc inhibitor known to date) over the last twenty years.Currently,cancer incidence in the world exceeds 14 million cases per year and results in 8 million deaths annually. Moreover, such numbers are forecast to rise by 75% over the next 20 years (World Cancer Report. International Agency for Research on Cancer 2014). At the moment, standard therapies include surgery, radiotherapy, chemotherapy, and, in a restricted subset of cancers, precision medicine. Unfortunately, very often these therapies fail, due to the development of resistance.Peptomyc has adopted a different strategy based on the inhibition of the oncoprotein Myc, which is found deregulated in the majority of human cancers. Myc holds a non-redundant function in cancer around which tumors cannot evolve, hence targeting Myc is the most promising therapeutic opportunity to date. Although Myc plays a central role in cancer there is currently no Myc inhibitor in the market. | $3.3M | Venture - Series Unknown | Jan 18, 2022 |  |
| Mediktor | Mediktor is the most advanced and accurate expert system for pre-diagnoses, triage and decision-making support.The first artificial intelligent system clinically validated that is transforming healthcare for everyone.A technology that finally makes it possible to reduce access barriers to healthcare:- Patients can make better decisionsfrom the first symptoms- And the healthcare system can organize its demand and optimize resources to offer a better medical coverage. | $12.8M | Venture - Series Unknown | Oct 04, 2021 |  |
| Binx Health | Binx Health is creating new categories of healthcare solutions that deliver on-demand testing to people where they need it most. With its proprietary, desktop, PCR-based point-of-care testing platforms and consumer mobile offerings, the company is redefining “convenient care” for the modern consumer | $104M | Series E | May 27, 2021 |  |
| INBRAIN Neuroelectronics | INBRAIN Neuroelectronics is pioneering real time precision neurology with the world’s first graphene-based brain-computer interface (BCI) therapeutics platform. Our technology combines precise BCI decoding with micrometric modulation to deliver adaptive, personalized treatments for conditions such as Parkinson’s disease, epilepsy, and strokerehabilitation. By providing continuous real-time monitoring and autonomous therapy adjustments, our AI-driven platform maximizes therapeutic outcomes while minimizing side effects. Through strategic collaborations, including with Merck KGAa and our subsidiary INNERVIA Bioelectronics, we are extending our innovative solutions to peripheral nerve and systemic disease applications, unlocking the potential of neurotechnology and bioelectronics. For more information, visit www.inbrain-neuroelectronics.com and follow us on LinkedIn. | $19.8M | Series A | Mar 26, 2021 |  |
| Inbiomotion | Inbiomotion is focused on the development and commercialization of a biomarker that predicts metastasis to improve patients' quality of life by personalizing the adjuvant treatment of early stage breast cancer. Founded in 2010 by Dr. Roger Gomis, it is a spin-off of IRB Barcelona and ICREA research institutions.Inbiomotion's uniquediagnostic assay is based on a highly selective single gene biomarker. Data generated thus far suggests such biomarker can identify early stage breast cancer patients that will benefit from bisphosphonate adjuvant treatment improving their overall and invasive disease free survival. It can further predict at an early stage a patient's risk of metastases relapse from primary tumors. The selectivity of the lead biomarker has the potential to advance the clinical standard of care using personalized medicine. |  | Venture - Series Unknown | Jan 21, 2021 |  |
| Peptomyc | Peptomyc is a company focused on the development of a new generation of cell-penetrating peptides (CPPs) targeting the Myc oncoprotein for cancer treatment. The company was founded in December 2014 and it is based on Dr. Soucek’s scientific research in Omomyc (the best direct Myc inhibitor known to date) over the last twenty years.Currently,cancer incidence in the world exceeds 14 million cases per year and results in 8 million deaths annually. Moreover, such numbers are forecast to rise by 75% over the next 20 years (World Cancer Report. International Agency for Research on Cancer 2014). At the moment, standard therapies include surgery, radiotherapy, chemotherapy, and, in a restricted subset of cancers, precision medicine. Unfortunately, very often these therapies fail, due to the development of resistance.Peptomyc has adopted a different strategy based on the inhibition of the oncoprotein Myc, which is found deregulated in the majority of human cancers. Myc holds a non-redundant function in cancer around which tumors cannot evolve, hence targeting Myc is the most promising therapeutic opportunity to date. Although Myc plays a central role in cancer there is currently no Myc inhibitor in the market. | $12.5M |  | Dec 15, 2020 |  |

10 of 18 investments shown.

## Co-investors
- [Asabys Partners](https://shizune.co/investors/profile/asabys-partners) — VC Fund, 5 deals together
- [Centre for the Development of Industrial Technology (CDTI)](https://shizune.co/investors/profile/centre-for-the-development-of-industrial-technology-cdti) — VC Fund, 5 deals together
- [Fund+](https://shizune.co/investors/profile/fund) — VC Fund, 4 deals together
- [Ysios Capital](https://shizune.co/investors/profile/ysios-capital) — VC Fund, 4 deals together
- [Healthequity](https://shizune.co/investors/profile/healthequity-2) — VC Fund, 3 deals together
- [ICF Capital](https://shizune.co/investors/profile/institut-catal-de-finances-icf) — VC Fund, 3 deals together

## Similar investors

### Similar industry
- [SOSV](https://shizune.co/investors/profile/sosv) — VC Fund
- [ARCH Venture Partners](https://shizune.co/investors/profile/arch-venture-partners) — VC Fund
- [OrbiMed](https://shizune.co/investors/profile/orbimed-advisors) — VC Fund

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

### Similar country
- [ENISA](https://shizune.co/investors/profile/enisa-2) — VC Fund
- [Inveready](https://shizune.co/investors/profile/inveready-technology-investment-group) — VC Fund
- [Angels Capital](https://shizune.co/investors/profile/angels-capital) — VC Fund

## Featured in investor lists
- [Health Care Investors in Spain](https://shizune.co/investors/health-care-investors-spain)
- [Health Care VC Funds in Spain](https://shizune.co/investors/health-care-vc-funds-spain)
- [Biotechnology Investors in Spain](https://shizune.co/investors/biotechnology-investors-spain)
- [Biotechnology VC Funds in Spain](https://shizune.co/investors/biotechnology-vc-funds-spain)
- [Biotech Investors in Spain](https://shizune.co/investors/biotech-investors-spain)
- [Biotech VC Funds in Spain](https://shizune.co/investors/biotech-vc-funds-spain)

## FAQ

### What does Alta Life Sciences invest in?

Alta Life Sciences invests primarily in Biotechnology, Health Care and Therapeutics startups, most often at Series A and Venture - Series Unknown stage. Most of the 18 investments tracked by Shizune back companies in Spain. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### What is Alta Life Sciences's check size?

Alta Life Sciences typically joins rounds of $3M–$33M at Series A, $13M–$87M at Series B and $3.3M–$13M at Venture - Series Unknown. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Alta Life Sciences participates in.

### How do I contact Alta Life Sciences?

Public channels for Alta Life Sciences include the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Alta Life Sciences?

The team at Alta Life Sciences includes Guy P. Nohra (Managing General Partner), Scott Moonly (General Partner) and José Antonio Mesa (Partner). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co